The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 226.50
Bid: 225.50
Ask: 227.50
Change: 0.00 (0.00%)
Spread: 2.00 (0.887%)
Open: 226.50
High: 229.00
Low: 225.00
Prev. Close: 226.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

25 Jan 2024 07:00

RNS Number : 8282A
PureTech Health PLC
25 January 2024
 

25 January 2024

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

24 January 2024

Number of ordinary shares purchased:

35,192

Highest price paid per share:

198.00p

Lowest price paid per share:

192.80p

Volume weighted average price paid per share:

195.69p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 18,884,863 ordinary shares in treasury and has 270,583,296 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 270,583,296 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

24/01/2024

08:29:27

815

192.8

XLON

00386861372TRLO0.1.1

24/01/2024

08:29:44

315

192.8

CHIX

00386861432TRLO0.1.1

24/01/2024

08:29:44

213

192.8

CHIX

00386861433TRLO0.1.1

24/01/2024

08:29:59

815

192.8

XLON

00386861483TRLO0.1.1

24/01/2024

08:30:43

916

192.8

XLON

00386861719TRLO0.1.1

24/01/2024

08:31:31

622

192.8

XLON

00386862022TRLO0.1.1

24/01/2024

08:34:33

515

192.8

XLON

00386862779TRLO0.1.1

24/01/2024

08:34:33

13

192.8

XLON

00386862780TRLO0.1.1

24/01/2024

08:39:41

528

192.8

XLON

00386864131TRLO0.1.1

24/01/2024

08:44:47

528

192.8

XLON

00386865524TRLO0.1.1

24/01/2024

09:32:54

6336

195

XLON

00386876245TRLO0.1.1

24/01/2024

09:34:07

173

195

CHIX

00386876729TRLO0.1.1

24/01/2024

09:34:36

96

195

CHIX

00386876791TRLO0.1.1

24/01/2024

09:37:02

2112

195.4

XLON

00386877399TRLO0.1.1

24/01/2024

09:37:08

528

194.8

BATE

00386877491TRLO0.1.1

24/01/2024

09:37:08

528

194.8

CHIX

00386877492TRLO0.1.1

24/01/2024

09:37:08

283

194.8

AQXE

00386877493TRLO0.1.1

24/01/2024

09:58:58

528

197

XLON

00386882071TRLO0.1.1

24/01/2024

10:00:28

193

197

CHIX

00386882619TRLO0.1.1

24/01/2024

10:00:28

291

197.2

CHIX

00386882620TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884053TRLO0.1.1

24/01/2024

10:08:52

1584

196.8

XLON

00386884055TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884054TRLO0.1.1

24/01/2024

10:08:52

342

196.6

TRQX

00386884056TRLO0.1.1

24/01/2024

10:16:28

1056

196.6

XLON

00386885232TRLO0.1.1

24/01/2024

10:16:28

481

196.6

XLON

00386885233TRLO0.1.1

24/01/2024

10:39:12

35

196.4

CHIX

00386889783TRLO0.1.1

24/01/2024

10:39:12

493

196.4

CHIX

00386889784TRLO0.1.1

24/01/2024

10:39:12

388

196.4

CHIX

00386889785TRLO0.1.1

24/01/2024

10:39:12

528

196.4

XLON

00386889787TRLO0.1.1

24/01/2024

10:39:12

575

196.4

XLON

00386889786TRLO0.1.1

24/01/2024

10:39:12

231

196.4

XLON

00386889788TRLO0.1.1

24/01/2024

10:39:12

148

196.4

XLON

00386889789TRLO0.1.1

24/01/2024

10:39:12

176

196.4

XLON

00386889790TRLO0.1.1

24/01/2024

10:39:13

35

196

BATE

00386889793TRLO0.1.1

24/01/2024

11:13:47

2112

196.4

XLON

00386895560TRLO0.1.1

24/01/2024

11:14:55

119

196.2

CHIX

00386895706TRLO0.1.1

24/01/2024

11:34:12

579

196.4

CHIX

00386898389TRLO0.1.1

24/01/2024

11:34:12

528

196.4

BATE

00386898390TRLO0.1.1

24/01/2024

11:34:12

2085

196.4

XLON

00386898391TRLO0.1.1

24/01/2024

11:48:28

528

196.8

XLON

00386901072TRLO0.1.1

24/01/2024

11:50:46

409

196.2

BATE

00386901394TRLO0.1.1

24/01/2024

11:50:46

2112

196.4

XLON

00386901395TRLO0.1.1

24/01/2024

12:20:02

528

197

XLON

00386906123TRLO0.1.1

24/01/2024

14:44:34

283

198

AQXE

00386943011TRLO0.1.1

24/01/2024

14:44:34

287

198

CHIX

00386943012TRLO0.1.1

24/01/2024

14:46:50

500

198

XLON

00386945228TRLO0.1.1

24/01/2024

14:46:50

154

198

CHIX

00386945227TRLO0.1.1

24/01/2024

14:46:50

52

198

TRQX

00386945229TRLO0.1.1

24/01/2024

14:46:50

28

198

XLON

00386945230TRLO0.1.1

24/01/2024

14:46:50

199

198

TRQX

00386945231TRLO0.1.1

24/01/2024

14:46:50

119

198

TRQX

00386945232TRLO0.1.1

24/01/2024

14:46:50

472

198

XLON

00386945233TRLO0.1.1

24/01/2024

14:46:50

56

198

XLON

00386945234TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945235TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945236TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTLIISFIS
Date   Source Headline
24th Mar 20217:00 amRNSHolding(s) in Company
18th Mar 20217:00 amRNSDirectorate Change
15th Mar 20217:00 amRNSNotice of Results
3rd Mar 202112:00 pmRNSPRTC Presents at Barclays Healthcare Conference
2nd Mar 20211:01 pmRNSKaruna Prices Approximately $250M Public Offering
25th Feb 20212:00 pmRNSPRTC Publishes Lymphatic Targeting Study for Glyph
25th Feb 20217:00 amRNSKaruna data in New England Journal of Medicine
18th Feb 202112:00 pmRNSPRTC Presents at SVB Leerink Healthcare Conference
10th Feb 20217:05 amRNSVor Closes Over $200M Initial Public Offering
10th Feb 20217:00 amRNSPRTC Receives $118M from Founded Entity Shares
8th Feb 202112:00 pmRNSVedanta Adds Biotech Finance and IR Expert as CFO
5th Feb 202111:46 amRNSPureTech Founded Entity Vor Lists on Nasdaq
5th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20217:00 amRNSPureTech Appoints Bharatt Chowrira to BOD
18th Jan 20217:00 amRNSVor Files IPO Registration Statement on Nasdaq
14th Jan 202112:05 pmRNSVor Announces FDA Acceptance of IND Application
14th Jan 202111:50 amRNSAesthetic Med & Dermatology Veterans Join Follica
12th Jan 202111:50 amRNSVedanta Receives $25M Investment from Pfizer Inc
5th Jan 20217:00 amRNSPRTC Appoints Biotech Analyst & Senior Exec as CFO
4th Jan 20217:00 amRNSTotal Voting Rights
21st Dec 202012:00 pmRNSPureTech to Present at JPM and Other Conferences
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202012:00 pmRNSPRTC Starts LYT-200 Clinical Trial in Solid Tumors
11th Dec 20207:00 amRNSHolding(s) in Company
10th Dec 202012:00 pmRNSLYT-100 Advances to Phase 2a Study in Lymphedema
9th Dec 202012:00 pmRNSFollica Female Hair Loss Academic Study Published
3rd Dec 202012:00 pmRNSPureTech Initiates Ph 2 of LYT-100 in Long COVID
1st Dec 20207:00 amRNSTotal Voting Rights
30th Nov 202012:00 pmRNSPureTech to Host Virtual R&D Day for Investors
27th Nov 20204:41 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
27th Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
27th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Nov 202012:00 pmRNSVedanta Appoints Karuna CFO Troy Ignelzi to BOD
23rd Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th Nov 20207:00 amRNSPRTC LYT-100 Shows PK & Tolerability Ph1 POC
16th Nov 20207:00 amRNSPureTech to Present at Three Investor Conferences
13th Nov 20205:05 pmRNSGuidance for Exchanging Ordinary Shares into ADSs
13th Nov 20205:00 pmRNSDirector/PDMR Shareholding
13th Nov 20201:04 pmRNSGelesis Presents New Data at The Liver Meeting
13th Nov 20207:00 amRNSPureTech to Commence Nasdaq Trading on 16 November
12th Nov 20202:04 pmRNSSonde Respiratory Portal Available to Developers
11th Nov 20201:03 pmRNSVor Licenses Clinical-Stage CD33 CAR-T Therapy
5th Nov 20207:00 amRNSPureTech Presents at Credit Suisse Conference
3rd Nov 20205:10 pmRNSGelesis Presents New Data at ObesityWeek
2nd Nov 20204:35 pmRNSDirector/PDMR Shareholding
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.